InspireMD Inc
NSPR
查看详细走势图
1.990USD
-0.010-0.50%
收盘 12/19, 16:00（美东）报价延迟15分钟
83.42M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.50%
5天
+2.05%
1月
+3.11%
6月
-19.11%
今年开始到现在
-24.33%
1年
-33.67%
查看详细走势图
TradingKey InspireMD Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
InspireMD Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在医疗设备与耗材行业排名87/208位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.50。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
InspireMD Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
4.500
目标均价
+147.25%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
InspireMD Inc亮点
亮点风险
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
业绩高增长
公司营业收入稳步增长，连续3年增长35.54%
业绩增长期
公司处于发展阶段，最新年度总收入7.01M美元
利润高增长
公司净利润处于行业前列，最新年度总收入7.01M美元
估值合理
公司最新PE估值-2.43，处于3年历史合理位
机构加仓
最新机构持股17.22M股，环比增加18.63%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值0.00
活跃度降低
近期活跃度降低，过去20天平均换手率0.67
InspireMD Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
InspireMD Inc简介
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
公司代码NSPR
公司InspireMD Inc
CEOSlosman (Marvin L)
网址https://www.inspiremd.com/en/
常见问题
InspireMD Inc(NSPR)的当前股价是多少？
InspireMD Inc(NSPR)的当前股价是 1.990。
InspireMD Inc的股票代码是什么？
InspireMD Inc的股票代码是NSPR。
InspireMD Inc股票的52周最高点是多少？
InspireMD Inc股票的52周最高点是3.798。
InspireMD Inc股票的52周最低点是多少？
InspireMD Inc股票的52周最低点是1.590。
InspireMD Inc的市值是多少？
InspireMD Inc的市值是83.42M。
InspireMD Inc的净利润是多少？
InspireMD Inc的净利润为-32.01M。
现在InspireMD Inc(NSPR)的股票是买入、持有还是卖出？
根据分析师评级，InspireMD Inc(NSPR)的总体评级为买入，目标价格为4.500。
InspireMD Inc(NSPR)股票的每股收益（EPS TTM）是多少
InspireMD Inc(NSPR)股票的每股收益（EPS TTM）是-0.820。
相关品种
-0.24%
+0.25%
+0.87%
+1.88%
+0.22%
-0.55%
+0.53%
+0.12%
+1.35%
-0.10%
-1.23%
-0.77%
+0.10%
+0.46%
+0.46%
+0.97%
+0.59%
+0.23%
+0.45%
+1.74%
